A Manhattan federal judge has rejected Martin Shrkeli’s bid to escape an antitrust lawsuit seeking to ban the imprisoned executive from ever working in the pharmaceutical industry, after the price of his company’s lifesaving drug, Daraprim, suddenly spiked more than 4,000% in 2015.

U.S. District Judge Denise L. Cote of the Southern District of New York said Tuesday there was reason to believe that alleged scheme at Shkreli’s Vyera Pharmaceuticals was still occurring, more than five years after the price of the company’s branded drug increased overnight to $750 per pill.